Lilly presents first clinical data in platinum-sensitive ovarian cancer for investigational ADC
LLY•Eli Lilly reported Phase 1 data for its investigational FRα-targeting ADC in platinum-sensitive ovarian cancer, with a confirmed objective response rate of 79% and disease control rate of 100%.
1. Phase 1 results
Eli Lilly presented its first clinical data for the investigational, next-generation FRα-targeting ADC in platinum-sensitive ovarian cancer. Phase 1 data showed a confirmed objective response rate of 79% and a disease control rate of 100%.
